JP7073281B2 - Ｌｐａアンタゴニストとしてのカルバモイルオキシメチルトリアゾールシクロヘキシル酸 - Google Patents

Ｌｐａアンタゴニストとしてのカルバモイルオキシメチルトリアゾールシクロヘキシル酸 Download PDF

Info

Publication number
JP7073281B2
JP7073281B2 JP2018566914A JP2018566914A JP7073281B2 JP 7073281 B2 JP7073281 B2 JP 7073281B2 JP 2018566914 A JP2018566914 A JP 2018566914A JP 2018566914 A JP2018566914 A JP 2018566914A JP 7073281 B2 JP7073281 B2 JP 7073281B2
Authority
JP
Japan
Prior art keywords
methyl
alkyl
independently selected
oxy
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018566914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518766A5 (OSRAM
JP2019518766A (ja
Inventor
ピーター・タイ・ワー・チェン
ロバート・エフ・カルテンバッハ・ザ・サード
ジュン・リ
シ・ジュン
ヤン・シ
シーウェイ・タオ
ジャン・ハオ
スレシュ・ダヌス
クマラベル・セルバクマール
ラメシュ・バブ・レディグンタ
スティーブン・ジェイ・ウォーカー
ローレンス・ジェイ・ケネディ
ジェイムズ・アール・コート
ファン・ティアナン
スチャノ・ユスフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019518766A publication Critical patent/JP2019518766A/ja
Publication of JP2019518766A5 publication Critical patent/JP2019518766A5/ja
Priority to JP2022078334A priority Critical patent/JP7312295B2/ja
Application granted granted Critical
Publication of JP7073281B2 publication Critical patent/JP7073281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/08—Saturated compounds containing ether groups, groups, groups, or groups
    • C07C62/10—Saturated compounds containing ether groups, groups, groups, or groups with a six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2018566914A 2016-06-21 2017-06-20 Ｌｐａアンタゴニストとしてのカルバモイルオキシメチルトリアゾールシクロヘキシル酸 Active JP7073281B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022078334A JP7312295B2 (ja) 2016-06-21 2022-05-11 Ｌｐａアンタゴニストとしてのカルバモイルオキシメチルトリアゾールシクロヘキシル酸

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662352792P 2016-06-21 2016-06-21
US62/352,792 2016-06-21
PCT/US2017/038216 WO2017223016A1 (en) 2016-06-21 2017-06-20 Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022078334A Division JP7312295B2 (ja) 2016-06-21 2022-05-11 Ｌｐａアンタゴニストとしてのカルバモイルオキシメチルトリアゾールシクロヘキシル酸

Publications (3)

Publication Number Publication Date
JP2019518766A JP2019518766A (ja) 2019-07-04
JP2019518766A5 JP2019518766A5 (OSRAM) 2020-05-28
JP7073281B2 true JP7073281B2 (ja) 2022-05-23

Family

ID=59258388

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018566914A Active JP7073281B2 (ja) 2016-06-21 2017-06-20 Ｌｐａアンタゴニストとしてのカルバモイルオキシメチルトリアゾールシクロヘキシル酸
JP2022078334A Active JP7312295B2 (ja) 2016-06-21 2022-05-11 Ｌｐａアンタゴニストとしてのカルバモイルオキシメチルトリアゾールシクロヘキシル酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022078334A Active JP7312295B2 (ja) 2016-06-21 2022-05-11 Ｌｐａアンタゴニストとしてのカルバモイルオキシメチルトリアゾールシクロヘキシル酸

Country Status (32)

Country Link
US (8) US10071078B2 (OSRAM)
EP (2) EP3472148B1 (OSRAM)
JP (2) JP7073281B2 (OSRAM)
KR (2) KR102463621B1 (OSRAM)
CN (2) CN114601830A (OSRAM)
AR (1) AR108838A1 (OSRAM)
AU (2) AU2017281439B2 (OSRAM)
CA (1) CA3029202C (OSRAM)
CL (1) CL2018003708A1 (OSRAM)
CO (1) CO2019000471A2 (OSRAM)
CY (2) CY1123443T1 (OSRAM)
DK (2) DK3472148T3 (OSRAM)
EA (1) EA037585B1 (OSRAM)
ES (2) ES2895385T3 (OSRAM)
HR (2) HRP20200586T1 (OSRAM)
HU (2) HUE057211T2 (OSRAM)
IL (1) IL263767B (OSRAM)
LT (2) LT3472148T (OSRAM)
ME (1) ME03804B (OSRAM)
MX (1) MX381205B (OSRAM)
MY (1) MY195782A (OSRAM)
PE (1) PE20190211A1 (OSRAM)
PL (2) PL3472148T3 (OSRAM)
PT (2) PT3666771T (OSRAM)
RS (2) RS60347B1 (OSRAM)
SG (1) SG11201811321TA (OSRAM)
SI (2) SI3666771T1 (OSRAM)
SM (2) SMT202100614T1 (OSRAM)
TW (2) TWI757128B (OSRAM)
UY (1) UY37302A (OSRAM)
WO (1) WO2017223016A1 (OSRAM)
ZA (1) ZA201808580B (OSRAM)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2019126085A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
EP3728210A1 (en) 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
SG11202005699QA (en) * 2017-12-19 2020-07-29 Bristol Myers Squibb Co Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
JP7212047B2 (ja) * 2017-12-19 2023-01-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
WO2019126098A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
ES2942767T3 (es) 2017-12-19 2023-06-06 Bristol Myers Squibb Co Isoxazol azoles del ácido ciclohexílico como antagonistas del LPA
ES2925626T3 (es) * 2017-12-19 2022-10-19 Bristol Myers Squibb Co Acidos isoxazol-O-carbamoilciclohexílicos como antagonistas de LPA
CN112055710B (zh) 2017-12-19 2025-01-28 百时美施贵宝公司 作为lpa拮抗剂的环己基酸吡唑吖嗪
KR102777148B1 (ko) 2017-12-19 2025-03-05 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 트리아졸 아진
US11319315B2 (en) * 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid triazole azoles as LPA antagonists
EP3728209B1 (en) 2017-12-19 2025-12-24 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as lpa antagonists
JP7427658B2 (ja) * 2018-09-18 2024-02-05 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロペンチル酸
EP3852747B1 (en) * 2018-09-18 2023-05-31 Bristol-Myers Squibb Company Cycloheptyl acids as lpa antagonists
US12428430B2 (en) 2018-09-18 2025-09-30 Bristol-Myers Squibb Company Oxabicyclo acids as LPA antagonists
US20210379210A1 (en) * 2018-10-15 2021-12-09 Bristol-Myers Squibb Company Radioligands for imaging the lpa1 receptor
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
CN111434653A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
CN113939502A (zh) * 2019-04-16 2022-01-14 百时美施贵宝公司 用于制备氨基甲酰氧基甲基三唑环己酸化合物的方法
JP7465899B2 (ja) * 2019-06-18 2024-04-11 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロブチルカルボン酸
KR20220024549A (ko) * 2019-06-18 2022-03-03 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 카르복실산
US12435057B2 (en) * 2019-06-18 2025-10-07 Bristol-Myers Squibb Company Triazole carboxylic acids as LPA antagonists
MX2022001264A (es) 2019-07-30 2022-02-22 Taisho Pharmaceutical Co Ltd Compuesto de urea para antagonizar el receptor del acido lisofosfatidico tipo 1.
JP7431961B2 (ja) 2019-11-15 2024-02-15 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニストとしてのトリアゾールカルバメートピリジルスルホンアミド及びその使用
EP4066895A1 (en) * 2019-11-29 2022-10-05 ONO Pharmaceutical Co., Ltd. Compound having lysophosphatidic acid receptor agonistic activity and pharmaceutical use of said compound
WO2021116259A1 (en) 2019-12-12 2021-06-17 Chiesi Farmaceutici S.P.A. Aromatic amido derivatives as lpa receptor 2 inhibitors
WO2021116257A1 (en) 2019-12-12 2021-06-17 Chiesi Farmaceutici S.P.A. Thienopyrimidine derivatives as lpa receptor 2 inhibitors
US12404270B2 (en) 2019-12-12 2025-09-02 Chiesi Farmaceutici S.P.A. Quinazoline derivatives as LPA receptor 2 inhibitors
CN111195254B (zh) * 2020-02-25 2021-03-16 中国医学科学院阜外医院 Lpa2及其激动剂的应用
KR102393079B1 (ko) 2020-02-28 2022-04-29 한국화학연구원 가축 호흡기 질환의 예방 또는 치료용 조성물
TWI838626B (zh) * 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CA3185689A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
ES2991765T3 (es) 2020-07-16 2024-12-04 Chiesi Farm Spa Derivados del ácido amido ciclohexano como inhibidores del receptor de LPA
US20240018102A1 (en) * 2020-10-22 2024-01-18 Lhotse Bio, Inc Compounds and compositions for treating conditions associated with lpa receptor activity
WO2022100625A1 (zh) * 2020-11-10 2022-05-19 武汉人福创新药物研发中心有限公司 氮取代氨基碳酸酯噻吩类化合物及其用途
CN114456147B (zh) * 2020-11-10 2025-07-15 武汉人福创新药物研发中心有限公司 氧取代氨基碳酸酯噻吩类化合物
CN114456159A (zh) * 2020-11-10 2022-05-10 武汉人福创新药物研发中心有限公司 氮取代杂环噻吩类化合物及其用途
CN114621135B (zh) * 2020-12-11 2024-01-30 上海拓界生物医药科技有限公司 一种lpa1小分子拮抗剂
CN112778187B (zh) * 2021-01-06 2022-10-28 烟台舜康生物科技有限公司 一种海那替尼中间体的合成方法及所得的海纳替尼中间体
WO2022174882A1 (en) 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
WO2022174883A1 (en) 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
EP4313956A1 (en) 2021-03-24 2024-02-07 Chiesi Farmaceutici S.p.A. 8-cyclo-substituted quinazoline derivatives as lpa receptor 2 inhibitors
CN117295717A (zh) 2021-05-11 2023-12-26 吉利德科学公司 Lpa受体拮抗剂及其用途
WO2022270621A1 (ja) * 2021-06-25 2022-12-29 公益財団法人がん研究会 骨肉腫及び神経膠腫の転移と増殖を抑制する新規治療薬
CA3224635A1 (en) * 2021-07-20 2023-01-26 Yunfei Li Lpa1 small molecule antagonist
WO2023066359A1 (en) * 2021-10-21 2023-04-27 Lhotse Bio, Inc. Compounds and compositions for treating conditions associated with lpa receptor activity
JP7709612B2 (ja) * 2021-12-08 2025-07-16 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
WO2023109878A1 (zh) * 2021-12-15 2023-06-22 武汉人福创新药物研发中心有限公司 三氮唑类lpar1拮抗剂及其用途
EP4452965A1 (en) 2021-12-23 2024-10-30 Chiesi Farmaceutici S.p.A. Cyclohexane acid derivatives as lpa receptor inhibitors
AR128613A1 (es) 2022-02-25 2024-05-29 Lhotse Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
US20250188068A1 (en) 2022-03-08 2025-06-12 Chiesi Farmaceutici S.P.A. Amido cyclopropyl derivatives as lpa receptor inhibitors
IL315605A (en) 2022-03-15 2024-11-01 Bristol Myers Squibb Co Biocatalytic synthesis of compounds of (1S,3S)-3-HYDROXYCYCLOHEXANE-1-CARBOXYLIC ACID
WO2024138190A1 (en) 2022-12-23 2024-06-27 Bristol-Myers Squibb Company Crystalline forms of a lpa1 antagonist
AU2023410896A1 (en) 2022-12-23 2025-08-07 Bristol-Myers Squibb Company Lpa1 antagonists for treating interstitial lung disease
US20240216352A1 (en) 2022-12-23 2024-07-04 Bristol-Myers Squibb Company Lpa1 antagonists for treating interstitial lung disease
KR20250123927A (ko) 2022-12-23 2025-08-18 브리스톨-마이어스 스큅 컴퍼니 간질성 폐 질환을 치료하기 위한 lpa1 길항제
TW202432092A (zh) 2023-01-19 2024-08-16 大陸商江蘇恒瑞醫藥股份有限公司 三氮唑類化合物的可藥用鹽、晶型及其製備方法
WO2025051266A1 (zh) * 2023-09-08 2025-03-13 西藏海思科制药有限公司 杂芳环衍生物的lpar1拮抗剂及其用途
WO2025051267A1 (zh) * 2023-09-08 2025-03-13 西藏海思科制药有限公司 一种lpar1拮抗剂及其用途
CN117024409A (zh) * 2023-10-10 2023-11-10 药康众拓(北京)医药科技有限公司 氘代lpa1抑制剂化合物及其用途
WO2025162421A1 (zh) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 Lpar1拮抗剂及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041694A2 (en) 2009-10-01 2011-04-07 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US20120115844A1 (en) 2010-11-09 2012-05-10 Maria-Clemencia Hernandez Novel triazole compounds i
WO2012062623A1 (en) 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Triazole derivatives as ligands for gaba receptors
WO2013189864A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag N-alkyltriazole compounds as lpar antagonists
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
US20140031353A1 (en) 2011-01-30 2014-01-30 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
US20140329871A1 (en) 2011-12-04 2014-11-06 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1695422A (en) 1928-12-18 A cobpobation
US1695432A (en) 1924-03-18 1928-12-18 Arthur W Lovejoy Toilet-paper holder
US1695455A (en) 1925-12-07 1928-12-18 Delpech Jacques Apparatus for the manufacture of artificial filaments
US1677284A (en) 1926-04-23 1928-07-17 Goodrich Co B F Sheet material and method of making and mounting the same
US1695431A (en) 1926-10-05 1928-12-18 Fred H Linley Combustion control in steam-boiler furnaces
GB267434A (en) 1926-11-12 1927-03-17 Thomas Whyte Guthrie An improved billiard-cue tip
US1695454A (en) 1927-05-23 1928-12-18 Edward J Coyne Door spring
IT1237793B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
ATE447970T1 (de) 2001-02-08 2009-11-15 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
BRPI0507501A (pt) 2004-02-18 2007-06-26 Astrazeneca Ab composto, composição farmacêutica, uso do composto, método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
DE102004038403B4 (de) 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
GB0806794D0 (en) 2008-04-15 2008-05-14 Ludwig Inst Cancer Res Therapeutic compounds
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
EA201390821A1 (ru) 2010-12-07 2013-10-30 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты и их применение
EP2694472B1 (en) 2011-04-05 2020-03-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
MA37762B1 (fr) 2012-06-20 2018-04-30 Hoffmann La Roche Composés n-aryltriazole utilisés comme antagonistes de lpar
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR108745A1 (es) 2016-06-21 2018-09-19 Syngenta Participations Ag Derivados de oxadiazol microbiocidas
JP7212047B2 (ja) 2017-12-19 2023-01-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
EP3728210A1 (en) 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
ES2925626T3 (es) 2017-12-19 2022-10-19 Bristol Myers Squibb Co Acidos isoxazol-O-carbamoilciclohexílicos como antagonistas de LPA
SG11202005699QA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
WO2019126098A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
CN112055710B (zh) 2017-12-19 2025-01-28 百时美施贵宝公司 作为lpa拮抗剂的环己基酸吡唑吖嗪
ES2942767T3 (es) 2017-12-19 2023-06-06 Bristol Myers Squibb Co Isoxazol azoles del ácido ciclohexílico como antagonistas del LPA
WO2019126085A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
EP3728209B1 (en) 2017-12-19 2025-12-24 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as lpa antagonists
KR102777148B1 (ko) 2017-12-19 2025-03-05 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 트리아졸 아진

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041694A2 (en) 2009-10-01 2011-04-07 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US20120115844A1 (en) 2010-11-09 2012-05-10 Maria-Clemencia Hernandez Novel triazole compounds i
WO2012062623A1 (en) 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Triazole derivatives as ligands for gaba receptors
US20140031353A1 (en) 2011-01-30 2014-01-30 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
US20140329871A1 (en) 2011-12-04 2014-11-06 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
WO2013189864A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag N-alkyltriazole compounds as lpar antagonists
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAKTHADOSS, M et al.，Synthesis of highly diversified 1,2,3-triazole derivatives via domino [3+2] azide cycloaddition and denitration reaction sequence，RSC Advances，2015年，Vol. 5，pp. 93447-93451

Also Published As

Publication number Publication date
ZA201808580B (en) 2020-08-26
EP3666771A1 (en) 2020-06-17
US20170360759A1 (en) 2017-12-21
CN114601830A (zh) 2022-06-10
JP7312295B2 (ja) 2023-07-20
ME03804B (me) 2021-04-20
CY1123443T1 (el) 2021-12-31
CA3029202A1 (en) 2017-12-28
EP3472148B1 (en) 2020-03-11
HUE057211T2 (hu) 2022-04-28
IL263767B (en) 2021-08-31
CO2019000471A2 (es) 2019-02-08
PL3666771T3 (pl) 2021-12-27
SI3472148T1 (sl) 2020-07-31
AU2017281439B2 (en) 2021-07-01
AU2021209334A1 (en) 2021-08-26
DK3472148T3 (da) 2020-04-27
CY1124737T1 (el) 2022-07-22
US20250057815A1 (en) 2025-02-20
IL263767A (en) 2019-01-31
PT3666771T (pt) 2021-10-27
CA3029202C (en) 2022-03-01
BR112018076558A2 (pt) 2019-04-02
ES2785951T3 (es) 2020-10-08
KR20220038537A (ko) 2022-03-28
US20230390249A1 (en) 2023-12-07
RS60347B1 (sr) 2020-07-31
TWI725200B (zh) 2021-04-21
DK3666771T3 (da) 2021-11-15
HRP20211708T8 (hr) 2022-03-04
RS62524B1 (sr) 2021-11-30
TW201808919A (zh) 2018-03-16
NZ750013A (en) 2022-03-25
EP3666771B1 (en) 2021-09-29
AU2017281439A1 (en) 2019-02-07
KR102377340B1 (ko) 2022-03-21
EA201892710A1 (ru) 2019-05-31
AR108838A1 (es) 2018-10-03
US20210244711A1 (en) 2021-08-12
LT3666771T (lt) 2021-12-10
US20200138789A1 (en) 2020-05-07
PT3472148T (pt) 2020-05-08
CN109963843B (zh) 2022-03-11
SI3666771T1 (sl) 2021-12-31
US10071078B2 (en) 2018-09-11
PL3472148T3 (pl) 2020-12-14
EA037585B1 (ru) 2021-04-19
HUE049944T2 (hu) 2020-11-30
TWI757128B (zh) 2022-03-01
KR102463621B1 (ko) 2022-11-03
MX2018015563A (es) 2019-06-06
AU2021209334B2 (en) 2023-06-01
US20180333395A1 (en) 2018-11-22
ES2895385T3 (es) 2022-02-21
WO2017223016A1 (en) 2017-12-28
SMT202000274T1 (it) 2020-07-08
MX381205B (es) 2025-03-12
LT3472148T (lt) 2020-05-25
UY37302A (es) 2018-01-02
PE20190211A1 (es) 2019-02-07
CN109963843A (zh) 2019-07-02
KR20190020049A (ko) 2019-02-27
US10576062B2 (en) 2020-03-03
USRE49352E1 (en) 2023-01-03
US11007180B2 (en) 2021-05-18
MY195782A (en) 2023-02-13
HRP20200586T1 (hr) 2020-07-10
JP2019518766A (ja) 2019-07-04
US20220249443A1 (en) 2022-08-11
TW202126629A (zh) 2021-07-16
JP2022106974A (ja) 2022-07-20
SMT202100614T1 (it) 2022-01-10
SG11201811321TA (en) 2019-01-30
EP3472148A1 (en) 2019-04-24
CL2018003708A1 (es) 2019-02-08
HRP20211708T1 (hr) 2022-02-04

Similar Documents

Publication Publication Date Title
JP7073281B2 (ja) Ｌｐａアンタゴニストとしてのカルバモイルオキシメチルトリアゾールシクロヘキシル酸
JP7274486B2 (ja) Ｌｐａアンタゴニストとしてのトリアゾールｎ結合カルバモイルシクロヘキシル酸
JP2021506863A (ja) Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール
JP2021506878A (ja) Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン
JP2021507896A (ja) Ｌｐａアンタゴニストとしてのイソキサゾールｎ結合カルバモイルシクロヘキシル酸
JP2021507895A (ja) Ｌｐａアンタゴニストとしてのピラゾールｎ−連結のカルバモイルシクロヘキシル酸
JP2021506859A (ja) Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン
JP2021507898A (ja) Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
JP2022500469A (ja) Ｌｐａアンタゴニストとしてのシクロヘプチル酸
HK40030550A (en) Lpa antagonists
HK40030550B (en) Lpa antagonists
HK40006813B (en) Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
HK40006813A (en) Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
BR112018076558B1 (pt) Ácidos cicloexil carbamoiloximetil triazol como antagonistas de lpa, composição farmacêutica e seus usos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220511

R150 Certificate of patent or registration of utility model

Ref document number: 7073281

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250